At a glance
ClinicalIndex Comparison Record- ✓Type 1 or type 2 diabetes mellitus
- ✓Best-corrected visual acuity better than 20/400 in study eye
- ✓Substantial retinal non-perfusion (>20 disc areas) by investigator assessment
- ✓Early proliferative diabetic retinopathy without vitreous hemorrhage; PRP can safely be deferred
- ✕Any prior systemic or intravitreal anti-VEGF treatment in study eye
- ✕Central retinal thickness >320 µm on SD-OCT
- ✕Evidence of infectious ocular infection at screening
- ✕History of vitreoretinal surgery in study eye
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating Aflibercept for Proliferative Diabetic Retinopathy. Completed, enrolled 43 participants across 4 sites.
Detailed Summary
The RECOVERY trial will assess the safety and tolerability of 2 mg intravitreal aflibercept injections (IAI) given monthly (Q4WK) or every 12 weeks (Q12WK) for the treatment of retinal capillary non-perfusion (RNP) associated with proliferative diabetic retinopathy (PDR). * Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 * Change in area of retinal capillary non-perfusion, as assessed by central reading center, from baseline through week 52
Study Details
Timeline
Interventions
Intravitreal injection